In summary, our data provide, for the first time, a new therapeutic vaccine against MUC1+ and PD-L1+ tumors, and provoke an enhanced anti-tumor immune response, thus controlling and regressing the tumor; this novel PD-L1-containing MUC1 tumor vaccine may have theoretical and clinical value in the application in tumor immunotherapy in human. This evidence concerns the gene MUC1 and neoplasm.